CorMedix Inc. (CRMD)

NASDAQ: CRMD · Real-Time Price · USD

8.17

+0.50 (6.52%)

Aug 18, 2026, 4:00 PM EDT - Market closed

6.52% (1D)

Market Cap	636.81M -34.0%
Revenue (ttm)	462.25M +280.5%
Net Income	186.02M +265.9%
EPS	2.08 +163.5%
Shares Out	77.94M
PE Ratio	3.92
Forward PE	29.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,033,423
Open	7.71
Previous Close	7.67
Day's Range	7.71 - 8.27
52-Week Range	6.13 - 14.96
Beta	1.50
Analysts	Buy
Price Target	15.40 (+88.49%)
Earnings Date	Aug 13, 2026

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 25, 2010

Employees 191

Stock Exchange NASDAQ

Ticker Symbol CRMD

Website https://cormedix.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for CRMD stock is "Buy." The 12-month stock price target is $15.4, which is an increase of 88.49% from the latest price.

Price Target

$15.4

(88.49% upside)

Analyst Consensus: Buy

Stock Forecasts

News

CorMedix reports Q2 EPS 29c vs. 28c last year

Reports Q2 revenue $101.93M, consensus $96.05M. Joseph Todisco, CorMedix (CRMD) chairman and CEO, commented, “CorMedix delivered a strong second quarter, generating $101.9 million in consolidated reve...

2 days ago - TheFly

CorMedix Earnings Call Transcript: Q2 2026

Q2 2026 revenue surged to $101.9M, driven by DefenCath and Melinta portfolio, with net income of $26M and adjusted EBITDA of $58.7M. Full-year guidance was reaffirmed and raised, while new supply agreements and positive clinical data support long-term growth.

5 days ago - Transcripts

CorMedix Earnings release: Q2 2026

CorMedix released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.

5 days ago - Filings

CorMedix Quarterly report: Q2 2026

CorMedix has published its Q2 2026 quarterly earnings report on August 13, 2026.

5 days ago - Filings

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒...

5 days ago - GlobeNewsWire

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before th...

20 days ago - GlobeNewsWire

CorMedix price target lowered to $13 from $14 at RBC Capital

RBC Capital lowered the firm’s price target on CorMedix (CRMD) to $13 from $14 and keeps an Outperform rating on the shares as part of a broader research note previewing…

6 weeks ago - TheFly

CorMedix Transcript: AGM 2026

The meeting saw the election of all director nominees, approval of executive compensation, and auditor ratification. Five charter-related proposals failed to pass. No questions were raised by stockholders during the session.

2 months ago - Transcripts

CorMedix announces United States Court of Appeals affirms patent judgements

CorMedix (CRMD) announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that…

2 months ago - TheFly

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of th...

2 months ago - GlobeNewsWire

CorMedix Transcript: Jefferies Global Healthcare Conference 2026

Management highlighted a transformation from a single-asset to a diversified institutional care company, driven by the Melinta acquisition and pipeline expansion. Key products REZZAYO and DefenCath are positioned for growth, with reimbursement and legislative changes as major catalysts. Guidance anticipates higher 2027 sales and continued business development.

2 months ago - Transcripts

CorMedix Slides: Corporate presentation

CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.

3 months ago - Filings

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2026

Preliminary REZZAYO data show efficacy and safety differentiation, with a broad FDA label sought and sNDA submission planned for H2. DefenCath guidance was raised on strong utilization, with 2027 revenue expected to rise as CMS reimbursement improves. Policy advocacy and pipeline expansion continue.

3 months ago - Transcripts

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Ca...

3 months ago - GlobeNewsWire

CorMedix Earnings Call Transcript: Q1 2026

Q1 2026 saw net revenue of $127.4M and adjusted EBITDA of $70M, driven by DefenCath and Melinta portfolio growth. Full-year guidance was raised for revenue and EBITDA, with DefenCath expected to see price changes post-reimbursement transition. REZZAYO's positive phase III results support an sNDA filing in H2 2026.